Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!


















Authors
 

Cadila Healthcare Share price, NSE/BSE Forecast News and Quotes| Equitymaster

Jun 18, 2021 | Updated on Jun 18, 2021

Cadila Healthcare: Get the latest Cadila Healthcare Share price and stock price updates, live NSE/BSE share price, share market reports, financial report, balance sheet, price charts, financial forecast news and quotes only at Equitymaster.com.

PICCADILY AG Share price, NSE/BSE Forecast News and Quotes| Equitymaster

Jun 18, 2021 | Updated on Jun 18, 2021

PICCADILY AG: Get the latest PICCADILY AG Share price and stock price updates, live NSE/BSE share price, share market reports, financial report, balance sheet, price charts, financial forecast news and quotes only at Equitymaster.com.

PICCADILY SU Share price, NSE/BSE Forecast News and Quotes| Equitymaster

Jun 18, 2021 | Updated on Jun 18, 2021

PICCADILY SU: Get the latest PICCADILY SU Share price and stock price updates, live NSE/BSE share price, share market reports, financial report, balance sheet, price charts, financial forecast news and quotes only at Equitymaster.com.

Cadila Healthcare Reports 73% Rise in Profits

May 28, 2021

A look into the company's quarter four financial performance.

Cadila: Racing ahead

Jul 9, 2002

A 16% rise in turnover reported by Cadila for FY02 is quite encouraging, especially considering the fact that the first half yearly growth was a mere 7%. On an annual basis, operating margins have also shown an improvement. The company has ambitious plans to emerge amongst the top 3 pharmaceutical companies in India by March 2004. Post the acquisition of controlling stake in German Remedies, the company is open to further in-organic growth.

Kopran: Lacks future clarity

Jan 3, 2002

Recently, Kopran sold its top selling Cardiovascular ‘Aten’ brand to Cadila for a consideration of Rs 950 m. The company is also believed to be in talks with other pharmaceutical majors for the sale of its remaining formulation business. Kopran seems to trying to change the perception and business profile to that of a company focused purely on the OTC segment. So far the company has met with initial success with its brand ‘Smyle’.

Cadila: Aggressive growth strategy

Dec 11, 2001

The performance of Cadila Healthcare, so far in the current year has been modest. It has been able to log less than 7% growth in topline for the first half of the current year. However, the company is on an acquisition spree to log faster growth through in-organic route.

Cadila Healthcare: Take care

May 3, 2001

Cadila Healthcare Ltd. results are below our expectations. Though, year on year basis sales have grown by 6.5% (expected 10.5%), it has infact showed a negative growth (2.7%) on a sequential basis. Operating margins have dipped from 18% in Q3FY01 to a paltry 5.9% in Q4FY01. The sudden drop in operating margins is unexplained at this point of time. Thanks to substantial reduction in interest cost and income from parking of IPO funds, bottomline showed an apparent growth of 64%.

Cadila: poor man's Cipla

Oct 23, 2000

Cadila Healthcare has also made its mark in the domestic pharmaceutical market thanks to the reverse engineering. The company was formed after the spilt in the partnership between the Patel and Modi groups. (The latter own Cadila Pharmaceuticals).


India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS